U.S. markets close in 1 hour 10 minutes
  • S&P 500

    4,373.23
    +16.78 (+0.39%)
     
  • Dow 30

    34,291.81
    -5.92 (-0.02%)
     
  • Nasdaq

    13,652.73
    +113.44 (+0.84%)
     
  • Russell 2000

    2,025.25
    +21.22 (+1.06%)
     
  • Crude Oil

    87.45
    +1.85 (+2.16%)
     
  • Gold

    1,827.50
    -25.00 (-1.35%)
     
  • Silver

    23.82
    -0.08 (-0.34%)
     
  • EUR/USD

    1.1259
    -0.0047 (-0.42%)
     
  • 10-Yr Bond

    1.8170
    +0.0340 (+1.91%)
     
  • GBP/USD

    1.3470
    -0.0036 (-0.26%)
     
  • USD/JPY

    114.5120
    +0.6460 (+0.57%)
     
  • BTC-USD

    37,755.35
    +537.91 (+1.45%)
     
  • CMC Crypto 200

    872.80
    +16.99 (+1.99%)
     
  • FTSE 100

    7,469.78
    +98.32 (+1.33%)
     
  • Nikkei 225

    27,011.33
    -120.01 (-0.44%)
     

Eisai: FDA confirms enough data to move Alzheimer's drug to Phase III studies

TOKYO, Aug 9 (Reuters) - Japan's Eisai Co said on Tuesday the U.S. Food and Drug Administration had confirmed that there was sufficient data to start Phase III studies of a drug it is co-developing to treat early Alzheimer's disease.

The investigational oral beta-secretase cleaving enzyme (BACE) inhibitor E2609 was discovered by Eisai and is being jointly developed with Massachusetts-based Biogen Inc, Eisai said in a statement.

Following the discussion with the FDA on the Phase III clinical study designs, Eisai and Biogen plan to have similar discussions with regulatory authorities in Japan and the European Union, Eisai said.

(Reporting by Chang-Ran Kim; Editing by Kim Coghill)